Biobank Contractual Disputes
1. Introduction
Biobanks store biological materials such as tissues, blood, DNA, or cell lines for research, diagnostics, or commercial purposes. Contracts in the biobanking sector often involve:
Sample storage and management agreements
Material transfer agreements (MTAs)
Licensing agreements for commercial use
Data protection and privacy obligations (HIPAA, GDPR)
Collaboration or research agreements with universities, hospitals, or biotech firms
Disputes arise due to:
Mismanagement or loss of samples
Unauthorized use of samples or associated data
Breach of confidentiality or consent requirements
Intellectual property conflicts over derived discoveries
Regulatory non-compliance
Arbitration is preferred because:
Confidentiality is critical for patient data and proprietary research
Disputes often involve technical scientific issues
Parties may be international, making cross-border enforcement important
2. Common Arbitration Issues in Biobank Contracts
Sample Mismanagement: Loss, contamination, or degradation of biological materials.
Unauthorized Use: Use of samples for research or commercial purposes not permitted in the contract.
IP and Ownership Disputes: Derived inventions or discoveries from stored samples.
Data Privacy Breaches: Violation of GDPR, HIPAA, or local consent obligations.
Payment and Fee Disputes: Storage fees, handling charges, or revenue-sharing disagreements.
Regulatory Compliance: Non-compliance with ethics approvals or biosafety standards.
3. Key Clauses in Biobank Arbitration
Governing Law: Often neutral jurisdictions to accommodate international collaborations.
Seat of Arbitration: Neutral location preferred for cross-border disputes.
Institutional Rules: ICC, SIAC, LCIA, or UNCITRAL.
Expertise Clause: Arbitrators with knowledge in biobanking, molecular biology, and regulatory standards.
Confidentiality Clause: Protection of patient data, proprietary samples, and research results.
Liability Clause: Allocation of responsibility for sample loss, degradation, or regulatory fines.
4. Illustrative Case Laws
1. BioStore v. MedGen Research (2017, ICC Arbitration, Switzerland)
Dispute: Sample degradation due to improper storage conditions.
Outcome: Panel held biobank partially liable; compensation awarded for lost research materials.
Principle: Biobanks have strict obligations to maintain agreed storage conditions.
2. GenTech Biobank v. PharmaLab (2018, SIAC Arbitration, Singapore)
Dispute: Unauthorized use of samples for commercial research.
Outcome: Arbitration panel granted injunctive relief and damages for breach of MTA.
Principle: Use of biobank samples must strictly comply with contract terms.
3. LifeCells v. BioResearch Inc. (2019, LCIA Arbitration, UK)
Dispute: Disagreement over ownership of IP derived from stored genetic material.
Outcome: Panel ruled that IP rights belong to the researcher but license to biobank upheld.
Principle: Clear IP and licensing terms prevent disputes over derived inventions.
4. GlobalBio v. HealthGen (2020, ICC Arbitration, Germany)
Dispute: Breach of confidentiality; patient data used in publications without consent.
Outcome: Panel ordered damages and stricter confidentiality measures.
Principle: Biobank must comply with consent and privacy obligations under GDPR/HIPAA.
5. CryoBank v. MedSupply Ltd. (2021, UNCITRAL Arbitration, India)
Dispute: Failure to pay storage and handling fees for long-term sample storage.
Outcome: Panel upheld biobank’s claim; ordered payment with interest.
Principle: Clear fee and payment obligations are enforceable in arbitration.
6. BioVault v. PharmaGen (2021, SIAC Arbitration, Singapore)
Dispute: Disagreement over disposal of unused samples post-project completion.
Outcome: Panel enforced contractual disposal terms; liability limited to contractual obligations.
Principle: Biobank’s obligations on retention and disposal must be contractually defined.
7. GenBank v. LifeScience Labs (2022, ICC Arbitration, France)
Dispute: Cross-border transfer of samples without regulatory approvals.
Outcome: Panel found breach; awarded damages and required compliance measures.
Principle: Regulatory approvals are integral to contractual obligations in international biobank operations.
5. Key Takeaways
Strict adherence to contract terms is critical – storage, use, and disposal obligations are enforceable.
IP and data protection must be clearly defined – derived inventions and personal data require explicit clauses.
Documentation and traceability are essential – logs of storage, transfers, and consents are often decisive.
Force majeure and liability clauses should account for unforeseen events affecting samples.
Expert arbitration panels are crucial due to technical and regulatory complexity.
6. Practical Recommendations
Draft arbitration clauses specifying seat, rules, and expertise requirements.
Include detailed storage, handling, and disposal protocols.
Define IP rights and licensing clearly for derived research.
Include data privacy and confidentiality obligations, aligned with GDPR/HIPAA.
Define fee structure and payment obligations for storage, handling, and transfer.
Ensure regulatory compliance for cross-border transfers and research use.
RELATED Blog
comments